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background: Patients with low LV ejection fraction (LVEF) are known to have worse mortality compared to those with preserved LVEF. However, it 
is unclear if the benefit of higher LVEF extends to those with very high LVEF values. We investigated the relationship between high LVEF (≥70%) and 
outcomes.
Methods: We included 23,817 veterans from 2007-2013 in 3 inpatient facilities and 8 county clinics who had their LVEF measured by echo. Cox 
Proportional Hazards and logistic regression models were used for statistical analyses.
results: The average age of the patients was 68 (±12) years. 47.9% of the patients had diagnosis of ischemic heart disease (IHD) and 76.6% of 
them had hypertension. 1,109 patients (6.3%) had high LVEF (≥70%), while LVEF was normal (50-69%) in 12,668 patients (71.5%), intermediate 
(40-49%) in 1,194 patients (6.7%), and low (<40%) in 2,747 patients (15.5%). This distribution was relatively similar across age groups. Blacks had 
higher rates of both high LVEF (7.9%) and low LVEF (16.9%), p<0.0001. The 1-year mortality rates in patients with high, normal, intermediate, and 
low LVEF categories were 21%, 17%, 20%, 24% for those with a prior diagnosis of HF (p<0.0001) and 17%, 10%, 13%, 18% for those without a prior 
diagnosis HF (p <0.0001). The 1-year mortality or readmission rates were 62% (low), 55% (intermediate), 46% (normal), and 53% (high), p <0.0001. 
Adjusted for demographics, comorbidities (including IHD and LV hypertrophy), and lab values, the hazard ratios for mortality were 1.2 (1.1-1.4) in 
those with high LVEF, 1.4 (1.2-1.5) in intermediate LVEF, and 1.7 (1.6-1.9) in low LVEF patients, compared to those with normal LVEF (all p<0.001). 
Odds ratios for 1-year mortality or hospitalization were similar; 1.2 (1.04-1.4) for high, 1.3 (1.1-1.5) for intermediate and 1.6 (1.4-1.7) for low, 
compared to those with normal LVEF (all p<0.001).
conclusion: There is a U shape relationship between LVEF and outcomes. In both patients with and without HF, those with an LVEF ≥70% have 
higher mortality and hospitalization rates than those with normal LVEF, even after adjustment for comorbidities. Further investigations are needed to 
evaluate possible mechanisms for worse outcomes in patients with high LVEF.
